06.08.16
Brammer Bio has unveiled plans to build-out a 50,000 sq. ft. facility dedicated to late phase development, including Phase III and commercial production of viral vector-based and cell-based advanced therapies. The Lexington, MA facility will be qualified and operational by Q2 of 2017. More than $50 million will be invested in the build-out of operations and growing the staff by up to 200, according to the company.
“We’re delighted to bring to reality full scale gene and cell therapy production in Massachusetts to serve the needs of our clients,” said Mark Bamforth, president and chief executive officer, Brammer Bio.
After completing a merger with Florida Biologix in March of 2016, the cell and gene therapy contract development and manufacturing organization (CDMO) will further solidify its technical and operational supply position through the build-out of the Lexington, MA facility.
Brammer Bio is building on Florida Biologix’s ten-year track record of manufacturing and testing to support clinical trials of advanced therapeutics. Florida Biologix was founded by Brammer Bio’s chief scientific officer, Richard Snyder, who has gained expertise through his 30-year career establishing cell and gene therapy manufacturing. The addition of large-scale and late-stage manufacturing at the Lexington, MA facility, in conjunction with the early clinical focus of the Florida location, provides clients with the start-to-finish capability of manufacturing and testing advanced cell and gene therapies.
“The Lexington facility will be equipped for large-scale manufacturing with a focus on compliance in these emerging drug categories, providing a reliable supply of high quality advanced therapies to our clients who are bringing their products to market,” said Dr. Snyder.
“We’re delighted to bring to reality full scale gene and cell therapy production in Massachusetts to serve the needs of our clients,” said Mark Bamforth, president and chief executive officer, Brammer Bio.
After completing a merger with Florida Biologix in March of 2016, the cell and gene therapy contract development and manufacturing organization (CDMO) will further solidify its technical and operational supply position through the build-out of the Lexington, MA facility.
Brammer Bio is building on Florida Biologix’s ten-year track record of manufacturing and testing to support clinical trials of advanced therapeutics. Florida Biologix was founded by Brammer Bio’s chief scientific officer, Richard Snyder, who has gained expertise through his 30-year career establishing cell and gene therapy manufacturing. The addition of large-scale and late-stage manufacturing at the Lexington, MA facility, in conjunction with the early clinical focus of the Florida location, provides clients with the start-to-finish capability of manufacturing and testing advanced cell and gene therapies.
“The Lexington facility will be equipped for large-scale manufacturing with a focus on compliance in these emerging drug categories, providing a reliable supply of high quality advanced therapies to our clients who are bringing their products to market,” said Dr. Snyder.